Celldex Therapeutics shares surge as lead asset shows promise in two skin conditions
By Eleanor Laise
Experimental treatment proves effective in treating hives and an inflammatory skin disease
Celldex Therapeutics (CLDX) shares jumped more than 30% premarket on Monday after the company released positive clinical trial results for its lead asset in both chronic hives and an inflammatory skin disease.
The treatment, a monoclonal antibody called barzolvolimab, produced clinically meaningful responses in patients with moderate to severe chronic spontaneous urticaria, which is characterized by hives that last six weeks or longer and have no identifiable causes, Celldex said in a release Monday.
Data from more than 200 patients showed that barzolvolimab achieved the study's primary goal, which was a statistically significant change in hives activity after 12 weeks, compared with a placebo, the biotech company said.
Separately, Celldex on Sunday released promising early-stage results from a trial of barzolvolimab in prurigo nodularis, a chronic skin disorder that causes an itchy rash. Celldex is looking to start a phase 2 study of the treatment in prurigo nodularis early next year, president and CEO Anthony Marucci said in a statement.
The early efficacy data are "highly encouraging" and support the thesis that the treatment could be a best-in-class therapy, Leerink Partners analysts said in a note Sunday.
Celldex shares have dropped 41.7% in the year to date, while the S&P 500 SPX has gained 13.5%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-06-23 0815ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst